Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDlasta follow-up in severe congenital neutropenia
IRCT20150125020786N3Phase 2Completed
- Sponsor
- Pooyesh Darou
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in severe congenital neutropenia (SCN), sponsored by Pooyesh Darou. Primary endpoints: Increase in absolute neutrophil count and Decrease in hospitalization due to infectious diseases. Started Jul 2018; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
severe congenital neutropenia (SCN)
Beyond the preview
Go deeper on IRCT20150125020786N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150125020786N3.